Atlas
Market PulseSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › CONCORDBIO

CONCORDBIO

Concord Biotech Limited
Small-capPharma ↗

What the six lenses say about CONCORDBIO — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1305.4
2026-07-10
VWAP · 1Y anchor
₹1298
+0.6% from VWAP
P/E · TTM
52.3×
TTM EPS ₹24.9
52-week range
31%
position low→high
RSI(14)
57
momentum

Own sector index

Pharma ↗
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How CONCORDBIO’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
3.0
avg conviction decile
Leadership
0/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Small-cap cohortDRaw
TechnicalD555›

The actual numbers

Price vs VWAP (1y)+0.6%
EMA trend stackMixed
Price vs 200-EMA-0.2%
Price vs 50-EMA+5.5%
RSI(14)57
RS vs Nifty 500 · 3M+19.8%
RS vs sector · 3M+7.4%
52-week range31%
Volume vs 30d avg0.41×
Volume vs 60d avg0.54×
ATR(14) · volatility50.1
Bollinger width · vol contraction0.110
FundamentalD444›

The actual numbers

Return on equity (ROE)13.8%
Return on capital (ROCE)18.2%
Operating margin32.7%
Net margin24.5%
Revenue growth · YoY-12.1%
EPS growth · YoY-29.8%
Debt / equity0.00×

Full 8-quarter history in the financials table below.

ValuationD420›

The actual numbers

P/E (TTM)52.3×
TTM EPS₹24.9
52-week range31%
CatalystD230›

The actual numbers

Earnings & momentum23
Capital actions19
Governance76

Every filing in the corporate-announcements panel below.

FlowD125›

The actual numbers

Promoter holding44.1%
Delivery · 30d avg41.3%
Up/down-day asymmetry-9.7pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D5 + D1 ) ÷ 2 = 3.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Medium
52
Conviction score 52/100 · avg-decile strength 3.0/10
Conviction score52/100›
TechnicalD5›
FundamentalD4›
ValuationD4›
CatalystD2›
FlowD1›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+3.3pp
+2.4pp
-5.1pp
+23.5pp
+5.6pp
-22.3pp
Nifty 500
Broad-market baseline
+2.9pp
+2.3pp
-5.7pp
+19.8pp
+0.5pp
-26.2pp
Sector
Own-sector index
—
—
-8.1pp
+7.4pp
-13.8pp
-44.0pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

CONCORDBIO daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1305.40+45.60

Relative strength

RS vs baseline · rebased to 100

CONCORDBIO ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
76.33+2.11

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)216310244430204247278326
↳ change QoQ—+43.7%-21.3%+76.1%-52.6%+21.1%+12.6%+17.3%
EBITDA (₹cr)92147113189618898118
EBITDA margin42.4%47.3%46.1%44.0%29.9%35.6%35.3%36.2%
PAT (₹cr)60967614044636488
↳ change QoQ—+60.7%-20.7%+84.4%-68.6%+43.2%+1.6%+37.5%
Net margin27.6%30.9%31.1%32.6%21.6%25.5%23.0%27.0%
EPS (₹)5.709.157.2613.424.216.086.168.49
D/E————————
YoY growth · Mar '26Revenue -24.2% YoYPAT -37.1% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 19 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 Jun '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 2 Jun '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 30 May '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 30 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 29 May '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    MEDIUMcapital
    Dividend
    ›

    A dividend declaration — a cash return to shareholders.

    View original filing on NSE ↗
  • 29 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 26 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 18 May '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds CONCORDBIO

Mutual funds holding CONCORDBIO (8)

FundWeightAUM ₹crGrade
DSP Small Cap Reg Gr0.76%18,358
Edelweiss Small Cap Reg Gr0.79%6,156
SBI Healthcare Opportunities Reg Gr1.84%4,998
DSP Healthcare Fund Reg Gr1.58%3,309
Tata India Pharma & Healthcare Reg Gr1.76%1,455
ITI Flexi Cap Reg Gr1.00%1,314
Baroda BNP P Hlth and Wellness RegGr1.45%544
Bandhan Healthcare Reg Gr0.68%311

ETFs holding CONCORDBIO (0)

No tracked ETF holds CONCORDBIO ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma